Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration

Shishido, Y. Yoshida, T. Oshida, K. Uchida, M.
Pharmacol Res Perspect. 2024 Oct;12(5):e70017. doi: 10.1002/prp2.70017.

Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion – Transporting Polypeptide 1B (OATP1B) – Mediated Clinical Drug-Drug Interactions

Feng, B. Liang, G. Zetterberg, C. Li, S. Huang, H. Williams, J.Gao, H. Morikawa, Y. Kumar, S.
Drug Metab Dispos. 2024 Aug 5:DMD-AR-2024-001792. doi: 10.1124/dmd.124.001792.

Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

Shimada, T.
Nihon Yakurigaku Zasshi. 2023;158(6):483-489. doi: 10.1254/fpj.23038.

Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

Miyake, T. Mochizuki, T. Nakagawa, T. Nakamura, M. Emoto, C. Komiyama, N. Hirabayashi, M. Tsuruta, S. Shimojo, T. Terao, K. Tachibana, T.
Br J Pharmacol. 2023 Oct 23. doi: 10.1111/bph.16270.

Establishment of hyperoxic cell culture system for predicting drug-induced liver injury: reducing accumulated lipids in hepatocytes derived from chimeric mice with humanized liver

Ohtsuki, Y. Sanoh, S. Yamao, M. Kojima, Y. Kotake, Y. Tateno, C.
J Toxicol Sci. 2023;48(2):99-108. doi: 10.2131/jts.48.99.

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Aljaber, M. Y. Orie, N. N. Raees, A. Kraiem, S. Al-Jaber, M. Samsam, W. Hamza, M. M. Abraham, D. Kneteman, N. M. Beotra, A. Mohamed-Ali, V. Almaadheed, M.
Future Sci OA. 2022 Jul 7;8(6):FSO805. doi: 10.2144/fsoa-2022-0006. eCollection 2022 Jul.

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

Sato, K. Sanoh, S. Ishida, Y. Tateno, C. Ohta, S. Kotake, Y.
J Toxicol Sci. 2022;47(7):277-288. doi: 10.2131/jts.47.277.

Elucidation of the species differences of epyrifenacil-induced hepatotoxicity between mice and humans by mass spectrometry imaging analysis in chimeric mice with humanized liver

Matsunaga, K. Abe, J. Ogata, K. Fukunaga, S. Kitamoto, S.
J Toxicol Sci. 2021;46(12):601-609. doi: 10.2131/jts.46.601.

Utility of Gottingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration

Ding, N. Yamamoto, S. Chisaki, I. Nakayama, M. Matsumoto, S. I. Hirabayashi, H.
Drug Metab Pharmacokinet. 2021 Dec;41:100408. doi: 10.1016/j.dmpk.2021.100408. Epub 2021 Jun 9.

Chimeric Mouse With Humanized Liver Is an Appropriate Animal Model to Investigate Mode of Action for Porphyria-Mediated Hepatocytotoxicity

Toxicol Pathol. 2021 Jul 9:1926233211027474. doi: 10.1177/01926233211027474.

Eguchi, A. Fukunaga, S. Ogata, K. Kushida, M. Asano, H. Cohen, S. M. Sukata, T.

Application of humanized mice to toxicology studies: Evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)

Journal Toxicologic Pathology 2021; 34(4): 283-297. doi: https://doi.org/10.1293/tox.2021-0027

Tomoya Yamada

Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)

Yamada, T. Cohen, S. M. Lake, B. G.

Crit Rev Toxicol. 2021;51(5):373-394. doi:10.1080/10408444.2021.1939654. Epub 2021 Jul 15.